摘要
目的:观察恩替卡韦联合肝动脉化疗栓塞(transcatheter arterial chemoembolization,TACE)治疗HBV-DNA阳性原发性肝癌患者的疗效。方法:64例HBV-DNA阳性原发性肝癌患者,随机分为两组,每组各32例。均给予TACE治疗。治疗组:在常规保肝治疗基础上加用恩替卡韦,0.5mg/日;对照组:常规保肝治疗。结果:两组转氨酶、胆红素在TACE后均明显升高(P<0.001),血清前白蛋白均降低(P<0.001);但对照组各指标变化较治疗组明显(P<0.05);治疗组HBV-DNA转阴率高于对照组(P<0.0001)。结论:恩替卡韦能有效抑制乙肝病毒复制,减轻TACE后肝损害,改善患者的预后。
Objective：To study the therapeutic efficacy of Entecavir with TACE for patients with primary liver cancer with HBV-DNA positive.Methods：64 patients were derided into the treamtment group and the control group,they were treated by TACE.The treamtment group were treamted by Entecavir.The control group were treamted by general remedy.Results：Transaminase and bilirubin were rised and Prealbumin（PA）were reduced in two groups after TACE,but there were significantly difference after treatment in the treamtment group compared with the control（P〈0.01）.Conclusion：Entecavir could relieve hepatic injury and improve prognosis of patients with primary liver cancer after TACE.
出处
《中国医药导刊》
2011年第3期463-464,共2页
Chinese Journal of Medicinal Guide
关键词
恩替卡韦
原发性肝癌
肝损害
经导管动脉化疗栓塞
预后
Entecavir
Primary liver cancer
Hepatic injury
Transcatheter arterial chemoembolization
Prognosis
